General News Regulated Oxurion Announces the Continuation of KALAHARI Phase 2, Part B Study in Diabetic Macular Edema Following Interim Analysis EN December 14, 2022
General News Oxurion To Participate in Upcoming Scientific and Investor Conferences EN September 12, 2022
General News Regulated Oxurion Announces Amendment to Funding Program with Negma Group for EUR 6 Million in Funding EN NL September 2, 2022
General News Oxurion Announces Presentations at Upcoming Scientific and Investor Conferences EN July 11, 2022
General News Oxurion Announces Two Presentations at The Macula Society 45th Annual Meeting EN June 13, 2022
General News Oxurion Announces Two Upcoming Presentations at The Macula Society 45th Annual Meeting EN June 3, 2022
General News Regulated Oxurion Announces Results of the Extraordinary Shareholders’ Meeting held on 24 May 2022 EN NL May 25, 2022
General News Oxurion Announces Upcoming Preclinical Presentation on THR-149 at KININ2022 EN May 24, 2022
General News Regulated Oxurion Announces Top-Line Results from Part A of Phase 2 INTEGRAL Trial Evaluating THR-687 for Treatment of Diabetic Macular Edema (DME) EN NL May 9, 2022
General News Regulated Oxurion Announces Results of the Extraordinary and Annual Shareholders’ Meetings of 3 May 2022 and Invitation to the Extraordinary Shareholders’ Meeting of 24 May 2022 EN NL May 6, 2022
General News Oxurion Announces Preclinical Data on THR-687 for the Treatment of Diabetic Macular Edema at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting EN May 3, 2022
General News Oxurion Announces Upcoming Preclinical Data Presentation on THR-687 for the Treatment of Diabetic Macular Edema at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting EN April 11, 2022
